Announced Thu, 23 Jul · 13:34 IST
Solara Q1 FY27: highest EBITDA and PAT in 18 quarters
Compliance View source PDF
SOLARA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-8.1%1-day move
₹537.80
prior close
₹530.00
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.6+0.8+0.6+6.8-8.1-6.6————————
Up moveDown movePending
AI summary
Solara reported Q1 FY27 revenues of INR 3,843 Mn, up 20% YoY. EBITDA rose 10% to INR 635 Mn and PAT grew 55% to INR 163 Mn, the highest in 18 quarters. Base business (ex-Ibuprofen) revenue up 24% YoY at INR 3,077 Mn with EBITDA up 8%. Net debt fell by INR 1,346 Mn to INR 4,795 Mn. Ibuprofen business posted an EBITDA loss of INR 87 Mn.
Likely market impact
Strong quarterly performance with best profitability in 18 quarters and meaningful debt reduction, though Ibuprofen drag continues to weigh on overall margins.